The evaluation of efficacy of bone marrow CD34+ and CD133 + cells, isolated from patients with acute myocardial infarction;Ocena efektywności izolacji komórek CD34+ i CD133+, uzyskanych ze szpiku kostnego chorych ze świezym zawałem miȩśnia sercowego

Acta Haematologica Polonica

Volumn 39, Issue 1, 2008, Pages 72-86

  Korycka, Anna ^a,c   Plewka, Michał ^b   Krawczyńska, Anna ^a   Zubkowicz, Marta ^a   Wierzbowska, Agnieszka ^a   Wrzesieńkuś, Agata ^a   Pluta, Agnieszka ^a   Krzemińska PakuŁa, Maria ^b   Robak, Tadeusz ^a  

^a Z Kliniki Hematologii Uniwersytetu Medycznego W odzi

^b Z Kliniki Kardiologii II Katedry Kardiologii Uniwersytetu Medycznego w odzi

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute myocardial infarction; Progenitor cells

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN;

ACUTE HEART INFARCTION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW CELL; CELL ISOLATION; CELL TRANSPLANTATION; CLINICAL ARTICLE; FOLLOW UP; HEART LEFT VENTRICLE PERFORMANCE; HUMAN; MONONUCLEAR CELL; PERFUSION;

EID: 45349100775     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Arai S, Klingemann HG. Hematopoietic stem cell transplantation: bone marrow vs. mobilized peripheral blood. Arch. Med. Res., 2003; 34: 545-553.
2. Broxmayer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D i wsp. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl. Acad. Sci. USA, 1989; 86: 3828-3832.
3. Cairo M, Magner JE. Placental and /or umbilical cord blood: An alternative source of hematopoietic stem cells for transplantation. Blood, 1997; 90: 4665-4678.
4. Urbaniak-Kujda D, Wołowiec D, Tomaszewska-Toporska B, Kapelko-Slowik K, Kuliczkowski K. Mezenchymalne komórki macierzyste: ich biologia i perspektywy zastosowań klinicznych. Acta. Haematol. Pol., 2005; 36: 161-166.
5. Hui JH, Ouyang HW, Hutmacher DW, Goh JC, Lee EH. Mesenchymal stem cells in musculoskeletal tissue enginieering: a review of recent advances in National University of Singapore. Ann. Acad. Med. Singapore, 2005; 34: 206-212.
6. Yen AH, Sharpe PT. Regeneration of teeth using stem cell-based tissue engineering. Expert Opin. Biol. Ther., 2006; 6: 9-16.
7. Góra-Tybor J, Krawczyńska A. Kra̧żza̧ce komórki śródbłonka - nieinwazyjny marker angiogenezy. Acta Haematol. Pol., 2007; 38: 195-202.
8. Asahara T, Nasuda H, Takahashi T i wsp. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res., 1999; 85: 221-228.
9. Brzozowski A, Dmoszyńska A. Perspektywy leczniczego zastosowania komórek macierzystych szpiku w chorobach niehematologicznych. Acta Haematol. Pol., 2003; 34: 139-149.
10. Shaw JP, Basch R, Shamamian P. Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45. Blood Cells Mol. Dis., 2004; 32: 168-175.
11. He X, Gonzalez V, Tsang A, Thompson J, Tsang TC, Harris DT. Differential gene expression profiling of CD34+ CD133+ umbilical cord blood hematiopoietic srem progenitor cells. Stem Cells Dev., 2005; 14: 188-198.
12. D'Arena G, Musto P, Cascavilla N, Di Giorgio G, Zendoli F, Carotenuto M. Human umbilical cord blood: Immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. Haematologica, 1996; 81: 404-409.
13. Kopeé-Szlȩzak J, Podstwka U. Komórki hematopoetyczne CD34+ krwi pȩpowinowej. Acta Haematol. Pol., 2001; 32: 61-69.
14. Langston JW. The promise of stem cells in Parkinson disease. J. Clin. Invest., 2005; 115: 23-25.
15. Forrester JS, Price MJ, Makkar RR. Stem cell repair of infarcted myocardium. An overview for clinicians. Circulation, 2003; 108: 1139-1145.
16. Beeres S, Bengel F, Bartunek J i wsp. Role of imaging in cardiac stem cell therapy. J. Am. Coll. Cardiol., 2007; 49: 1137-1148.
17. Fernández-Avilés F, San Roman JA, Garcia-Frade J. i wsp. Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ. Res., 2004; 95: 742-748.
18. Schachinger V, Assmus B, Britten MB i wsp. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J. Am. Coll. Cardiol., 2004; 44: 1690-1696.
19. Wollert KC, Meyer GP, Lotz J i wsp. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet, 2004; 364: 141-148.
20. Fotino M, Merson EJ, Allen FH. Micromethod for rapid separation of lymphocytes from peripheral blood. Ann. Clin. Lab. Sci., 1971; 1: 131-133.
21. Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand. J. Immunol., 1976; 5 supl. 5: 9-15.
22. Korycka A, Smolewski P, Robak T. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs in vitro. Eur. J. Haematol., 2004; 73: 418-426.
23. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+cell counts based on the ISHAGE guidelines. Cytometry, 1998; 34: 61-70.
24. Basso G, Timeus F. Cytofluorometric analysis of CD34 cells. Bone Marrow Transplant. 1998; 22, Supl. 5: 17-20.
25. Leuner S, Arland M, Kahl C, Jentsch-Ulrich K, Franke A, Hoffkes HG. Enumaration of CD34-positice hematopoietic progenitor cells by flow cytometry: comparison of valumetric assay and ISHAGE gating strategy. Bone Marrow Transplant. 1998; 22: 699-706.
26. Plewka M, Krzemińska-Pakuła M, Korycka A, Jeżewski T, Kasprzak JD. Transplantacja komórek macierzystych u pacjentów z zawalem serca- fakty i mity. Pol. Przegl. Kardiol., 2006; 8: 422-425.
27. Plewka M, Krzemińska - Pakuła M, Jeżewski T, Lipiec P, Wierzbowska K, Peruga JZ, Korycka A, Robak T, Kasprzak JD. Wczesna ocena rezerwy wieńcowej w badaniu echokardiograficznym po dowiencowym podaniu jednoja̧drzastych komórek szpiku kostnego w grupie pacjentów po zawale. Pol. Przegl. Kardiol., 2008 (w druku).
28. Strauer BE, Brehm M, Zeus T, i wsp. Repair infarcted myecardium by autologous intracoronary mononuclear bone marrow cells transplantation in humans. Circulation. 2002; 106: 1913-1918.
29. Schächinger V, Erbs S, Elsässer A i wsp. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J., 2006; 27: 2775-2783.
30. Bartunek J, Vanderheyden M, Vandekerckhove B i wsp. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction; feasibility and safety. Circulation, 2005; 112 [suppl I]:178-183.
31. Janssens S, Dubois C, Bogaert J i wsp. Autologous bone marrow derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet, 2005; 367: 113-121.
32. Lunde K, Solheim S, Aakhus S i wsp. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med., 2006; 355: 1199-1209.
33. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood, 2005; 106: 1901-1910.
34. Laird D, von Andrian UH, Wagers AJ. Stem cell trafficking in tissue development, growth, and disease. Cell, 2008; 132: 612-630.
35. Turan RG, Brehm M, Koestering M i wsp. Factors influencing spontaneous mobilization of CD34+ and CD133+ progenitor cells after myocardial infarction. Eur. J. Clin. Invest., 2007; 37: 842-851.
36. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Forfang K. Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand. Cardiovasc, 2005; 39: 150-158.
37. Seeger F, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mono nuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J. 2007; 28: 766-772.